Abstract
SPECT and PET myocardial perfusion imaging (MPI) are widely used to evaluate patients for coronary artery disease. Regadenoson (a selective A2A adenosine receptor agonist) is a commonly used vasodilator agent for stress MPI because of its safety profile and ease of use. Common adverse reactions such as headache, shortness of breath, flushing, and chest and abdominal discomfort are typically mild and can be effectively reversed using methylxanthines such as aminophylline and caffeine. Neurological adverse reactions such as seizure and stroke have rarely been reported with the use of regadenoson. The hemodynamic changes associated with regadenoson administration, such as an exaggerated hypotensive or hypertensive response, may be the cause for the reported cerebrovascular accidents. Activation of central nervous system A2A adenosine receptors is thought to be responsible for seizure episodes in patients with or without known histories of seizure. A2A adenosine receptors activation is also believed to play a role in headaches and migraine. This patient reported who has a history of hemiplegic migraine developed left side weakness and headache following the administration of regadenoson during a PET MPI study. Imaging work-up to rule out cerebrovascular accident was normal. After 1 hour from the onset of his symptoms, his weakness and headache significantly improved with complete resolution within 24 hours. We concluded that regadenoson triggered a hemiplegic migraine episode in this patient, which has not been previously reported in the literature. It may be prudent to avoid regadenoson and adenosine use in patients with a history of hemiplegic migraine.
Similar content being viewed by others
Abbreviations
- SPECT:
-
Single photon emission tomography
- PET:
-
Positron emission tomography
- MPI:
-
Myocardial perfusion imaging
- CAD:
-
Coronary artery disease
- STEMI:
-
ST elevation myocardial infarction
- DES:
-
Drug-eluting stent
- tPA:
-
Tissue plasminogen activator
- LAD:
-
Left anterior descending coronary artery
- RCA:
-
Right coronary artery
- LCx:
-
Left circumflex coronary artery
- ECG:
-
Electrocardiogram
- NIHSS:
-
National Institutes of Health Stroke Scale
- cAMP:
-
Cyclic adenosine monophosphate
References
Prescribing Information: Lexisan (regadenoson) injection for intavenous use. https://www.astellas.us/docs/lexiscan.pdf Accessed May 1, 2021.
Gordi T, Frohna P, Sun HL, Wolff A, Belardinelli L, Lieu H. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. Clin Pharmacokinet 2006;45:1201-12.
Al Jaroudi W, Iskandrian AE. Regadenoson: A new myocardial stress agent. J Am Coll Cardiol 2009;54:1123-30.
Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 2007;14:645-58.
Russell MB, Ducros A. Sporadic and familial hemiplegic migraine: Pathophysiological mechanisms, clinical characteristics, diagnosis, and management. Lancet Neurol 2011;10:457-70.
Vongvaivanich K, Lertakyamanee P, Silberstein SD, Dodick DW. Late-life migraine accompaniments: A narrative review. Cephalalgia 2015;35:894-911.
Hendel RC, Bateman TM, Cerqueira MD, Iskandrian AE, Leppo JA, Blackburn B, et al. Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging. J Am Coll Cardiol 2005;46:2069-75.
Fried NT, Elliott MB, Oshinsky ML. The role of adenosine signaling in headache: A review. Brain Sci 2017;7.
Guieu R, Devaux C, Henry H, Bechis G, Pouget J, Mallet D, et al. Adenosine and migraine. Can J Neurol Sci 1998;25:55-8.
Lykke Thomsen L, Kirchmann Eriksen M, Faerch Romer S, Andersen I, Ostergaard E, Keiding N, et al. An epidemiological survey of hemiplegic migraine. Cephalalgia 2002;22:361-75.
Dorbala S, Ananthasubramaniam K, Armstrong IS, Chareonthaitawee P, DePuey EG, Einstein AJ, et al. Single photon emission computed tomography (SPECT) myocardial perfusion imaging guidelines: Instrumentation, acquisition, processing, and interpretation. J Nucl Cardiol 2018;25:1784-846.
Page RL 2nd, Spurck P, Bainbridge JL, Michalek J, Quaife RA. Seizures associated with regadenoson: A case series. J Nucl Cardiol 2012;19:389-91.
Junpaparp P, Rammohan HRS, Buppajarntham S, Figueredo VM. A rare complication of a common stress test. J Cardiol Cases 2014;10:43-5.
Radwan SS, Schwartz OG. Seizure: An adverse effect of regadenoson in myocardial perfusion imaging. Case Rep Cardiol 2019;2019:6240605.
Henzlova MJ, Duvall WL, Einstein AJ, Travin MI, Verberne HJ. ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers. J Nucl Cardiol 2016;23:606-39.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Elsadany, M., McMahon, S.R., Mehla, S. et al. Hemiplegic migraine episode triggered by regadenoson. J. Nucl. Cardiol. 29, 3469–3473 (2022). https://doi.org/10.1007/s12350-021-02736-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12350-021-02736-1